Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach

References

• SelbyJV, PengT, KarterAJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004;10(2 Pt 2):163–170.15005509
   PubMed Web of Science ®Google Scholar
• PatraCN, KumarAB, PanditHK, SinghSP, DeviMV. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride. Acta Pharm. 2007;57(4):479–489. doi:10.2478/v10007-007-0038-018165191
   PubMedGoogle Scholar
• KiortsisDN, GiralP, BruckertE, TurpinG. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25(6):445–451. doi:10.1046/j.1365-2710.2000.00315.x11123498
   PubMed Web of Science ®Google Scholar
• BangaloreS, KamalakkannanG, ParkarS, MesserliFH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. doi:10.1016/j.amjmed.2006.08.03317679131
   PubMed Web of Science ®Google Scholar
• NishioS, WatanabeH, KosugeK, UchidaS, HayashiH, OhashiK. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28(3):223–227. doi:10.1291/hypres.28.22316097365
   PubMed Web of Science ®Google Scholar
• LeeJW, MorrisJK, WaldNJ. Grapefruit juice and statins. Am J Med. 2016;129(1):26–29. doi:10.1016/j.amjmed.2015.07.03626299317
   PubMed Web of Science ®Google Scholar
• ParkCG, LeeH, ChoiJW, LeeSJ, KimSH, LimHE. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther. 2010;48(8):497–503. doi:10.5414/CPP4849720650039
   PubMed Web of Science ®Google Scholar
• SinhaV, KumriaR. Colonic drug delivery: prodrug approach. Pharm Res. 2001;18(5):557–564. doi:10.1023/A:101103312152811465408
   PubMed Web of Science ®Google Scholar
• LeopoldCS. Coated dosage forms for colon-specific drug delivery. Pharmaceut Sci Tech Today. 1999;2(5):197–204. doi:10.1016/S1461-5347(99)00151-0
   PubMedGoogle Scholar
• KimC. Advanced Pharmaceutics: Physicochemical Principles. CRC; 2004.
   Google Scholar
• ShahHP. Quality by design enabled development and optimization of gastroretentive floating matrix tablets of dipyridamole. Asian J Pharm. 2017;11(02).
   Google Scholar
• RapalliVK, KhosaA, SinghviG, GirdharV, JainR, DubeySK. Application of QbD principles in nanocarrier-based drug delivery systems. In: Pharmaceutical Quality by Design. Academic Press; 2019:255–296.
   Google Scholar
• TheismannE-M, KepplerK, OwenM, SchwarzK, SchlindweinWJP. Modelling the effect of process parameters on the wet extrusion and spheronisation of high-loaded nicotinamide pellets using a quality by design approach. Pharmaceutics. 2019;11(4):154. doi:10.3390/pharmaceutics11040154
   Web of Science ®Google Scholar
• NayakAK, AhmedSA, BegS, TabishM, HasnainMS. Application of Quality by design for the development of biopharmaceuticals. In: Pharmaceutical Quality by Design. Elsevier. 2019:399–411.
   Google Scholar
• AbdohA, Al-OmariM, BadwanA, JaberA. Amlodipine besylate-excipients interaction in solid dosage form. Pharm Dev Technol. 2004;9(1):15–24. doi:10.1081/PDT-12002741415000463
   PubMed Web of Science ®Google Scholar
• BandelinFJ. Compressed tablets by wet granulation. Pharma Dosage Forms. 1989;2:131–193.
   Google Scholar
• SolankiHK, BasuriT, ThakkarJH, PatelA. Recent advances in granulation technology. Int J Pharm Sci Rev Res. 2010;5(3):48–54.
   Google Scholar
• BeckerD, RigassiT, Bauer-BrandlA. Effectiveness of binders in wet granulation: a comparison using model formulations of different tabletability. Drug Dev Ind Pharm. 1997;23(8):791–808. doi:10.3109/0363904970915055024359330
   PubMed Web of Science ®Google Scholar
• RoweRC, SheskeyPJ, OwenSC, AssociationAP, LibraryR. Handbook of Pharmaceutical Excipients. Vol. 4. Pharmaceutical press London; 2003.
   Google Scholar
• LinSY, ChengCL, LinPC. Preparation and evaluation of sodium diclofenac controlled-release tablets. Pharm World Sci. 1995;17(2):42–47. doi:10.1007/BF018750537795557
   PubMedGoogle Scholar
• BharateS, BharateS, BajajA. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excip Food Chem. 2016;1(3):1131.
   Google Scholar
• RaoMS, MadhuriK, GvK. Formulation and evaluation of controlled release floating tablets of lamivudine employing HPMC K4M and sodium alginate.Pharm Sci Res 2013;4(1):396.
   Google Scholar
• RoweR, SheskeyP, QuinnM. Handbook of Pharmaceutical Excipients. Vol. 18. 7th. Pharm Dev Technol; 2013
   Google Scholar
• KhanAM, HanifM, BukhariNI, et al. Artificial Neural Network (ANN) approach to predict an optimized pH-dependent mesalamine matrix tablet. Drug Des Devel Ther. 2020;14:2434–2449. doi:10.2147/DDDT.S244016
   Web of Science ®Google Scholar
• BhoopBSJPT. Quality by Design (QbD) for holistic pharma excellence and regulatory compliance. Pharm Times. 2014;46(8):26–33.
   Google Scholar
• AsgharLFA, ChandranS. Design and evaluation of matrices of Eudragit with polycarbophil and carbopol for colon-specific delivery. J Drug Target. 2008;16(10):741–757. doi:10.1080/1061186080247334519005938
   PubMed Web of Science ®Google Scholar
• MarvolaM, NykänenP, RautioS, IsonenN, AutereAM. Enteric polymers as binders and coating materials in multiple-unit site-specific drug delivery systems. Eur J Pharm Sci. 1999;7(3):259–267. doi:10.1016/S0928-0987(98)00032-39845814
   PubMed Web of Science ®Google Scholar
• RockvilleM.The United States Pharmacopeial Convection. 16th. ed The United States pharmacopeia. The national formulary.; 1985. USP 21st revision (January 1, 1985)
   Google Scholar
• KwakHH, KimJO, ChungHK, et al. Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. Biopharm Drug Dispos. 2006;27(3):141–145. doi:10.1002/bdd.49516400620
   PubMed Web of Science ®Google Scholar
• GaoY, ShaoJ, JiangZ, et al. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Discov Today. 2014;19(3):326–340. doi:10.1016/j.drudis.2013.11.02024295642
   PubMed Web of Science ®Google Scholar
• EzzetF, KrishnaG, WexlerDB, StatkevichP, KosoglouT, BatraVK. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther. 2001;23(6):871–885. doi:10.1016/S0149-2918(01)80075-811440287
   PubMed Web of Science ®Google Scholar
• SuttleAB, PollackGM, BrouwerKL. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration–time profiles. Pharm Res. 1992;9(3):350–356. doi:10.1023/A:10158909188831614968
   PubMed Web of Science ®Google Scholar
• WangB, ShengL, LiY. Simultaneous determination of telmisartan and amlodipine in dog plasma by LC–MS-MS. J Chromatogr Sci. 2015;53(10):1708–1713. doi:10.1093/chromsci/bmv07826142429
   PubMed Web of Science ®Google Scholar
• ShanmugamS, RyuJ-K, YooS-D, ChoiH-G, WooJ-S. Evaluation of pharmacokinetics of simvastatin and its pharmacologically active metabolite from controlled-release tablets of simvastatin in rodent and canine animal models. Biomol Ther. 2011;19(2):248–254. doi:10.4062/biomolther.2011.19.2.248
   Web of Science ®Google Scholar
• ShitaraY, SugiyamaY. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105. doi:10.1016/j.pharmthera.2006.03.00316714062
   PubMed Web of Science ®Google Scholar
• SawadaT, SakoK, YoshiharaK, NakamuraK, YokohamaS, HayashiM. Timed‐release formulation to avoid drug–drug interaction between diltiazem and midazolam. J Pharm Sci. 2003;92(4):790–797. doi:10.1002/jps.1033612661064
   PubMed Web of Science ®Google Scholar
• Tubic-GrozdanisM, HilfingerJM, AmidonGL, et al. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res. 2008;25(7):1591–1600. doi:10.1007/s11095-007-9519-618213452
   PubMed Web of Science ®Google Scholar
• ToutainP-L, Bousquet‐MélouA. Plasma terminal half‐life. J Vet Pharmacol Ther. 2004;27(6):427–439. doi:10.1111/j.1365-2885.2004.00600.x15601438
   PubMed Web of Science ®Google Scholar